<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://www.cdti.es/en">
<channel>
<title>INVESTMENT</title>
<link>http://www.cdti.es/en</link>
<description/>
<language>en</language>
<item>
<title>El CDTI Innovación y Suma Capital invierten en WATTWIN, la plataforma que digitaliza los servicios de venta de proyectos fotovoltaicos</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-y-suma-capital-invierten-en-wattwin-la-plataforma-que-digitaliza-los</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The Innovation and CDTI Suma Capital invested in WATTWIN, the platform which digitizes the sales of photovoltaic project</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Thu, 02/27/2025 - 12:10</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-02-21T12:00:00Z" class="datetime">21 February 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The Innovation and CDTI Suma Capital invested in WATTWIN, the platform which digitizes the sales of photovoltaic project</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI innovation, through its programme invests and jointly with Suma Capital, through its merits SC ENION I ENERGY FUND, F.C.R.E. has reached an agreement with the partners of INTEGRAL SERVICE TO Energy infrastructure, S.L. to invest in the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-02/coinversion_wattwin.jpg" width="680" height="340" alt="Coinversión WATTWIN" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">Wattwin is a technological platform optimizes the marketing and management of projects produced solar, efficiency and electrification installer that attracts traders and engineering, which are driving energy transition in Spain. The investment of CDTI Innovation allows the company to make progress in the development of their technology and continue to grow in the sector.</p><p class="text-align-justify">Josep-Miquel Torregrosa, partner of Suma Capital, he stressed: “ since<a href="www.sumacapital.com" rel="noopener" target="_blank">Suma Capital</a>relying on technological solutions that accelerate energy transition. Wattwin is a great example of how the digitization can make more efficient energy sector and facilitate its adoption on a large scale, both residential and industrial level. The entrance to the CDTI Innovation reinforces the strength of the project and allow the company to continue to grow and improve its value proposition ".</p><p class="text-align-justify"><a href="www.sumacapital.com" rel="noopener" target="_blank">Suma Capital</a>it is an independent manager alternative assets, leader in ecological transition. Signature focuses its investments in sustainability through three different programmes: Infraestructuras Sostenibles, Capital Crecimiento and Venture Capital. Suma Capital, which manages more than eur 1 billion in assets, was founded in 2007 and has become a true european presence in Barcelona, Madrid and paris.<br /></p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 21 Feb 2025 12:15:19 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22377 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, FCR y SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, en QUIBIM, S.L., empresa de tecnología biomédica</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-sabadell-asabys-health-innovation-investments-ii-fcr</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., company biomedical technology</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/29/2025 - 14:05</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-29T12:00:00Z" class="datetime">29 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., company biomedical technology</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., has reached an agreement to enter the capital of the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_quibim.jpg" width="1024" height="512" alt="Coinvrersión QUIBIM" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify"><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>leading company in health technology and pioneer in the transformation of medicine as precision machining using biomarkers of image, announced the closure of its funding round Number for a total of 50 million. The round was led by<a href="www.asabys.com" title="Asabys partners">Asabys</a>through its merits Sabadell Asabys II, and Buenavista Equity Partners, through the BHG I, created in partnership with Columbus Venture Partners, with the participation of new investors as UI Investissements and GoHub Ventures, in addition to current investors in Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund fund) and Build Collective, Tony Fadell. Between prominent individual investors is dr. Jonathan Milner, founder of Abcam plc —<br /><br /><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>works with the ambitious aim to understand what is happening in each of the tissues of the human body, at any time and a noninvasive. To achieve this, the company develops models of IA applied to medical image to extract useful information from mri (RM), assessed (TC) and ct emission positrons (PET). These developments can characterize the phenotype results and to predict accurately in Clinical oncology, as the immunology, neuroscience and study of metabolic disorders.</p><p class="text-align-justify"><img alt="QR PROSTATE" data-entity-type="file" data-entity-uuid="8de4e3c9-20ef-4361-8a77-c3eab58962b0" src="http://www.cdti.es/sites/default/files/inline-images/qp-prostate_2.png" width="1920" height="1011" loading="lazy" /></p><p class="text-align-justify">A viewer prostate RM einforme structured to atlas of the prostate, with the presence of an injury.</p><p class="text-align-justify">With the financing of the Series A,<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>consolidates a strong presence in united states, following its success in europe, through strategic partnerships with hospitals and pharmaceutical companies. In line with its strategic plan and building on its range of solutions authorized by the FDA, the company will support to hospitals and clinical researchers in the efficient processing of large volumes of data from medical imaging. In Addition, the image solutions IA driven<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>will allow pharmaceutical companies to significantly improve the effectiveness of their clinical trials and accelerate the development of drugs, providing useful and accurate information derived from biomarkers of image.</p><p> </p><h4><strong>QUIBIM</strong></h4><p class="text-align-justify"><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>it is a health technology company pioneer in the development of tools that extract and processed information hides in medical imaging for improving clinical outcomes for patients.<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>it is at the forefront of research of biomarkers of image in life sciences, encouraging the development of advanced algorithms that convert the image data indictable predictions in oncology, immunology and neurology. The company uses the capabilities of the magnetic resonance imaging (MRI), computerized tomography (CT) and emission positrons (PET) to create medical devices, integrated perfectly into the flows of care providers around the world.</p><p class="text-align-justify">More than 170 health institutions, research centres, hospitals and clinics Quibim use throughout the world. In addition,<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>collaborates with Merck KGaA in the development of models of biomarkers of image you predict the response of oncological patients to allergies and inspiring decisions in their overall efforts of new drugs, as well as with Philips in the launching of image solutions and generates reports based on IA for prostate cancer.<br /><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>has offices in new York (USA), Cambridge (Uk), Valencia, Madrid and Barcelona (España).</p><p> </p><h4><strong>ASABYS PARTNERS</strong></h4><p class="text-align-justify"><a href="www.asabys.com" title="Asabys partners">Asabys Partners</a>it is a venture capital firm specialized in the health sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, and with the support of Banc Sabadell as anchor. Asabys investor invests in innovative companies and disruptive covering medical needs not covered in the vertical biofarma and health. Investment in the company comes from their vehicles Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR SA.</p><p> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Wed, 29 Jan 2025 11:39:30 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22233 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-en-la-empresa-estrategica-oncomatryx-biopharma-sl-pionera-en</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 01/28/2025 - 16:31</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-28T12:00:00Z" class="datetime">28 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p>The CDTI Innovation through the co-investment in strategic enterprises of its agenda Innvierte, has reached an agreement with the partners of ONCOMATRYX BIOPHARMA S.L. to enter the capital of the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_oncomatryx_biopharma.jpg" width="680" height="340" alt="Coinversión ONCOMATRYX BIOPHARMA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The pioneering work<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>focuses on the development of customized biofarmacéuticos medicines against tumor microambiente, to address invasive stages of cancer, which still have a high mortality rate.</p><p class="text-align-justify">After 14 years of research, the company<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx Biopharma</a>has received some promising results in the clinical trial phase I of its latest generation drug OMTX 705. OMTX 705 is a conjugated antibody (ADC) directed against the microambiente surrounding the tumor and favour their immunosuppression, invasion and metastasis. The results of the clinical trial have confirmed the efficacy and safety of OMTX705, as demonstrated in animal models.</p><p class="text-align-justify"><a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>located in the Parque tecnológico de Bizkaia, has identified new mechanisms and protein peritumoral estroma, cells and extracellular matrix that surround the tumor and facilitate their invasividad, immunosuppression, resistance to treatment and metastasis.</p><p class="text-align-justify"><a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>has addressed the development of these pioneers drugs mechanisms and protein peritumoral estroma, in collaboration with leading universities, hospitals and research centres in the usa and europe, such as Harvard university, MD Anderson Cancer Center, university of Stuttgart, university of turin, university of bologna, CIC-Biogune, research centre of Salamanca, national research Centre Of Oncological, Onkologikoa, Hospital Virgen del Rocío, Hospital Sant Joan de Deu Hospital Universitario de Valdecilla, Hospital 12 october, Catalan Institute of oncology and University Clinic of navarre.</p><p class="text-align-justify">It is noteworthy that the funds of the capital increase, along with recurrent income<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>from these licence agreements with large international biofarmacéuticas, will provide new cohorts of expansion in clinical trials, which will allow for a best characterization of proven effectiveness. Furthermore, it will be allocated to the clinical development of new drugs (antibodies because) of the pipeline of<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>against microambiente microenvironment.</p><h4> </h4><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 28 Jan 2025 11:46:31 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22228 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-inveready-biotech-iv-scr-sa-inveready-biotech-iv</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/29/2025 - 11:31</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-24T12:00:00Z" class="datetime">24 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">El CDTI Innovación, a través de su programa Innvierte, conjuntamente con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A. ha alcanzado un acuerdo con los socios de GENIOVA TECHNOLOGIES S.L, para invertir en la compañía</p></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_geniova.jpg" width="817" height="408" alt="Coinversión GENIOVA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The company<a href="https://geniova.com/" rel="noopener" target="_blank">Geniova Technologies S.L.</a>, in the area of wholesale trade of dental products, has developed a new technology of aligners with a new product, accelerating the movement of the teeth, to accelerate the process of alignment.</p><p class="text-align-justify">The commitment by Geniova CDTI, accompanied by the participation of current shareholders of the company, emphasizes the reliance on the potential of the hybrid technical Geniova. An invisible braces which combines the advantages of the modern aligners and the brackets, reaching 94 per cent of predictability. With FDA approved in United states and by investing Geniova received, will strengthen its presence in Europe, america and Asia, while promoting initiatives of R & D and sustainable production. The support of the CDTI Innvierte reinforces the long-term strategy of the company and the mutual commitment to promote health technologies with a positive impact in society.</p><h4 class="text-align-justify"><br /><strong>GENIOVA TECHNOLOGIES</strong></h4><p class="text-align-justify">Geniova is pioneer in orthodontics invisible, with more than 10 years of research and development devoted to refine its patented hybrid technique. This innovative system combines comfort with a removable aligners lingual arc nickel and titanium (NiTi), capable to match the speed of the fixed braces. Since its inception, has revolutionized Geniova invisible braces, providing effective treatment, invisible and secure environment capable of reaching a rate of predictability of 94 per cent. In Addition, it integrates greening initiatives and manufacturing practices responsible in each stage of its production, strengthening their global positioning and commitment to sustainability, innovation and excellence in orthodontics.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>INVEREADY</strong></h4><p class="text-align-justify"><a href="https://inveready.com/" rel="noopener" target="_blank">Inveready</a>it is an alternative asset manager leader in southern europe with more than eur 2 billion in assets under management and a strong focus on technological companies of high growth. With more than 15 years of trajectory reified sales and 64, provides financing solutions to companies throughout the life cycle, since the initial phase to the most advanced.<br /></p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 24 Jan 2025 11:39:32 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22220 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI invierte, junto con NARA CAPITAL, en Tesai Care SL, empresa de dispositivos médicos para prevenir y tratar la atrofia muscular respiratoria con electroestimulación no invasiva</title>
<link>http://www.cdti.es/noticias/el-cdti-invierte-junto-con-nara-capital-en-tesai-care-sl-empresa-de-dispositivos-medicos</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests, together with NARA CAPITAL, in Tesai Care SL, medical devices to prevent and treat respiratory muscle atrophy electrostimulation with non-invasive</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/15/2025 - 07:40</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-10T12:00:00Z" class="datetime">10 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests, together with NARA CAPITAL, in Tesai Care SL, medical devices to prevent and treat respiratory muscle atrophy electrostimulation with non-invasive</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation invests, together with NARA HEALTH CAPITAL I, F.C.R., TESAI CARE S.L., a start-up of medical technology that develops heecap ®, medical device of the non-invasive electrostimulation and custom designed to prevent and treat the atrophy respiratory muscle (diaphragm and abdominal) in patients who are in Intensive care units (UCI) supports Mechanical Ventilation and works in a synchronized with the patient</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_tesai_care.jpg" width="836" height="418" alt="Coinversión TESA CARE" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" target="_blank">CDTI Innovation</a>through its programme, together with Innvierte<a href="https://www.nara.capital/" rel="noopener" target="_blank">NARA HEALTH CAPITAL I, F.C.R.</a>, has reached an agreement with the partners of TESAI CARE, S.L., to enter the capital of the company.</p><p class="text-align-justify"><a href="www.heecap.com" rel="noopener" target="_blank">Tesai Care S.L.</a>it is a spanish medtech spin-off Parc Taulí Hospital and Hospital Vall d ’ Hebron that is developing heecap ® a device that provides a Unique treatment strategy in the area of health, based on the non-invasive electrical stimulation to maintain the strength of respiratory muscle in patients who need support mechanical ventilation (VM).</p><p class="text-align-justify">The VM is a technique that saves lives in critical patients, but presents a major challenge: 76 per cent of patients ventilated develop respiratory muscle atrophy because prolonged disused diaphragm and other respiratory muscles, a problem that affects more than 3 million people per year throughout the world. This weakness makes the disconnection of ventilation, which prolonged stays in the UCI and delay recovery.</p><p class="text-align-justify">The device heecap ® uses estimulación eléctrica transcutánea de los músculos Respiratorios (TERM, by its initials in english), sincronizándose with the patient to strengthen the muscles inspiratorios and espiratorios. With this technique, is to upgrade the muscular strength and facilitate the process of disengagement from the mechanical ventilation.</p><p class="text-align-justify">The device consisting of three main components: electrodes being placed on the patient and adapt in a personalized way, a device of electrical stimulation, and an algorithm that synchronizes the stimulation with respiratory cycles.</p><p class="text-align-justify">Tesai Care launched last october a clinical trial with the device heecap ®, after the approval of the spanish agency of medicines and Productos Sanitarios (AEMPS), for the purpose of confirming the safety and integrity of the system, as well as to confirm that the algorithm operates with precision.</p><p class="text-align-justify"> </p><p class="text-align-justify"><img alt="Heecap device" data-entity-type="file" data-entity-uuid="3d56db58-fb6b-4101-b494-8f316f373836" src="http://www.cdti.es/sites/default/files/inline-images/dispositivo_heecap_utilizado_por_enfermera_en_hospital_parc_tauli.jpeg" width="1440" height="1080" loading="lazy" /></p><p class="text-align-justify">Heecap device being used by a nurse in Hospital Parc Taulí<br /></p><p class="text-align-justify">The funds contributed by CDTI INNVIERTE and NARA CAPITAL combined with public and private financing, the company will enable progress in clinical studies needed for the market heecap ®, with the purpose of seeking the CE marking as a health product in 2026.</p><p class="text-align-justify">heecap ® has the potential to significantly improve the quality of life of patients critics, accelerating their autonomy, reducing the days of mechanical ventilation and income in the UCI, and reducing potential complications to income, such as infections. According to the canadian medical recognized intensivista Ewan Goligher, “ technical approximation heecap has the potential to become a new standard of treatment for patients ventilated ”.<br /></p><h4 class="text-align-justify"><strong>NARA HEALTH CAPITAL I, F.C.R.</strong></h4><p class="text-align-justify">Nara Capital management is a private capital invested in Biopharma businesses and HealthTech from technology transfer of research centres. Nara invests in projects and disruptive transformers in their initial stages of research and development.</p><p class="text-align-justify">Nara takes its in-depth knowledge of the sector to incorporate capital and operational capacities to startups, with the dual aim to generate long-term value their investors and create a positive impact on health and quality of life of patients and of society.</p><p class="text-align-justify"> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 10 Jan 2025 12:42:56 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22153 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI invierte junto con Ysios Capital y Asabys Partners en Anaconda Biomed, empresa de dispositivos médicos neurovasculares</title>
<link>http://www.cdti.es/noticias/el-cdti-invierte-junto-con-ysios-capital-y-asabys-partners-en-anaconda-biomed-empresa-de</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests together with Ysios Capital and Asabys Partners in Anaconda Biomed, medical devices company neurovasculares</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/15/2025 - 12:27</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-09T12:00:00Z" class="datetime">09 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests together with Ysios Capital and Asabys Partners in Anaconda Biomed, medical devices company neurovasculares</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation invests, together with YSIOS BIOFUND II INNVIERTE F.C.R, YSIOS BIOFUND II SIDE FUND F.C.R.E., SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, F.C.R. and ASABYS TOP UP FUND F.C.R., ANACONDA BIOMED S.L, company dedicated to the design, development and manufacture of medical devices neurovasculares. Its innovative product is the ANA Funnel Catheter, an advanced system designed to maximize the efficacy and safety of the mechanical trombectomías in the treatment of acute ischaemic stroke</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_anaconda_09012025.jpg" width="836" height="418" alt="Coinversión ANACONDA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte Ysios Capital and Asabys Partners, has reached an agreement with Anaconda Biomed to invest in the company.</p><p class="text-align-justify">Anaconda Biomed, based in spain, is in advanced stages clinics with your device ANA Funnel Catheter, a pioneering system designed to improve both efficiency as the safety of mechanical trombectomías in the treatment of acute ischaemic stroke, a major cause of death and disability in the world.</p><p class="text-align-justify">With a social and economic impact significantly, the stroke represents a critical challenge to the global level. According to recent data the stroke will affect the 25 per cent of adults aged 25 plus throughout their lives and represents an annual cost of more than eur 60 billion in europe. The innovation of Anaconda Biomed aligns itself with the public health goals, providing tools to address this issue.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>ANA Funnel Catheter</strong></h4><p class="text-align-justify">ANA5 Advanced Neurovascular Access ™ (ANA Funnel Catheter) is a catheter designed to help neurovasculares procedures. The device consisting of a mesh of nitinol radiopaco in a sweep topped with a layer polimérica that allows for the arrest local flow. Currently, this catheter is a device under investigation and is not available for sale in the united states or in the european union.</p><h4 class="text-align-justify"><br /><strong>Anaconda Biomed</strong></h4><p class="text-align-justify">Anaconda Biomed is an innovative company medical technology solutions to the latest generation trombectomía for the treatment of ischaemic stroke in the heart of its portfolio of products is ANA Funnel Catheter.</p><p class="text-align-justify">Anaconda Biomed has received funding of leading firms in life sciences, as Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell and private investors. Moreover, through public subsidies, the company has been supported by INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI, E.P.E, Enisa, CDTI (Neotec), the ministry of science and innovation (programmes and Emplea Retos), the EIB EIT and Health.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>Ysios Capital Partners</strong></h4><p class="text-align-justify">Ysios Capital is a spanish leading manager in venture capital which provides funding to enterprises of life sciences highly innovative treatments that are aimed at indications with a large medical need not covered. With offices in San Sebastian and Barcelona, is formed by a team of professionals diverse which aims to transform the capital in medical breakthroughs with a positive impact on society. Ysios Capital, founded in 2008, has more than eur 400 million in assets under management through its three funds.</p><h4 class="text-align-justify"><br /><strong>Asabys Partners</strong></h4><p class="text-align-justify">Asabys Partners is a specialized risk capital in health, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, with the support of the Banco Sabadell anchor. investor With around €300 million in assets under management and 18 owned Asabys invests in innovative companies disruptive and addressing unmet medical needs in the areas of biotechnology and pharmaceuticals and health technology investment in this company has been made since their vehicles Sabadell Asabys Health Innovation Investments SCR, SA, and Asabys Top Up Fund, RCF.</p><p class="text-align-justify"> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Thu, 09 Jan 2025 15:16:34 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22150 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI compromete más de 1.000 millones en fondos de capital riesgo y en coinversiones a través de Innvierte</title>
<link>http://www.cdti.es/noticias/el-cdti-compromete-mas-de-1000-millones-en-fondos-de-capital-riesgo-y-en-coinversiones</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI commits more than 1,000 million euros in venture capital funds and co-investments through Innvierte.</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 12/10/2024 - 16:36</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-12-03T12:00:00Z" class="datetime">03 December 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI commits more than 1,000 million euros in venture capital funds and co-investments through Innvierte.</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><ul><li class="text-align-justify">El Consejo de Administración de Innvierte ha aprobado en julio, septiembre, octubre y noviembre compromisos de participación en 17 fondos de capital riesgo, con una aportación global de 1.007 millones de euros</li>
<li class="text-align-justify">Se han aprobado además 26 nuevas coinversiones en los sectores Bio, Salud y Agroalimentación (10), TIC (7), Industria (6), Energía y Medio Ambiente (2) y Otros (1) y dos coinversiones estratégicas, con un compromiso global de aportación de Innvierte de 51 millones de euros</li>
</ul></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-12/3dic-np_innvierte_cdas_2o_semestre_2024_0.jpg" width="1024" height="512" alt="Datos Consejos Innvierte semestre 2 2024" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-adjunto-nota-de-prensa">
<div class="field field--name-field-adjunto-nota-de-prensa field--type-entity-reference field--label-hidden field__item"><div>
<span class="link">
<a href="http://www.cdti.es/sites/default/files/2024-12/2024_12_03_nota_de_prensa_fondoscoinversion-consejos_de_innvierte_jul-nov.pdf" target="_blank"><span class="icon-download"></span> Descargar documento adjunto </a></span>
</div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">El CDTI Innovación, Entidad Pública Empresarial (E.P.E.) adscrita al Ministerio de Ciencia, Innovación y Universidades, ha comprometido a través de Innvierte un paquete de participación en diecisiete fondos de capital riesgo y 28 coinversiones superior a los 1.000 millones de euros, que fueron aprobados por los Consejos de Administración de Innvierte de los pasados 30 de julio, 11 de septiembre, 11 de octubre y 29 de noviembre.</p>
<p class="text-align-justify">En concreto, los compromisos de participación en diecisiete fondos de capital riesgo ascienden a una aportación global, por parte de Innvierte, de 1.006,9 millones de euros, según en siguiente desglose:<br />
</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">17 fondos de capital riesgo</th>
<th class="text-align-center" scope="col" style="width: 151px;">Compromisos de Innvierte (M€)</th>
</tr></thead><tbody><tr><td style="width: 401px;">6 Generalista</td>
<td class="text-align-center" style="width: 151px;">535,2</td>
</tr><tr><td style="width: 401px;">4 Bio, Salud y Agroalimentación </td>
<td class="text-align-center" style="width: 151px;">207,7</td>
</tr><tr><td style="width: 401px;">5 TIC</td>
<td class="text-align-center" style="width: 151px;">211,0</td>
</tr><tr><td style="width: 401px;">1 Industria</td>
<td class="text-align-center" style="width: 151px;">28,5</td>
</tr><tr><td style="width: 401px;">1 Energía y Medio Ambiente</td>
<td class="text-align-center" style="width: 151px;">24,5</td>
</tr><tr><td class="text-align-right" style="width: 401px;"><strong>Total</strong></td>
<td class="text-align-center" style="width: 151px;"><strong>1.006,9</strong></td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Con respecto a la fase de desarrollo o madurez de los fondos en los que se ha comprometido la participación (2 en Cataluña, 12 en Madrid y 3 en el País Vasco), siguiendo las definiciones acordadas entre las principales asociaciones europeas de capital riesgo, se reparten del siguiente modo:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Madurez fondo </th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de fondos</th>
</tr></thead><tbody><tr><td style="width: 401px;">Semilla</td>
<td class="text-align-center" style="width: 151px;">4</td>
</tr><tr><td style="width: 401px;">Arranque</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">Otras fases iniciales</td>
<td class="text-align-center" style="width: 151px;">5</td>
</tr><tr><td style="width: 401px;">Later stage venture</td>
<td class="text-align-center" style="width: 151px;">2</td>
</tr><tr><td style="width: 401px;">Capital desarrollo </td>
<td class="text-align-center" style="width: 151px;">5</td>
</tr></tbody></table><p> </p>
<h4 class="text-align-justify"><strong>Compromisos de coinversión </strong></h4>
<p class="text-align-justify">Conjuntamente, se han aprobado también coinversiones en 26 empresas (de las cuales 8 son empresas nuevas en Innvierte), con un compromiso de aportación de Innvierte de 38,5 millones de euros, según el siguiente desglose:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">26 empresas con 27 rondas aprobadas</th>
<th class="text-align-center" scope="col" style="width: 151px;">Compromisos de Innvierte (M€)</th>
</tr></thead><tbody><tr><td style="width: 401px;">10 empresas de Bio, Salud y Agroalimentación</td>
<td class="text-align-center" style="width: 151px;">16,9</td>
</tr><tr><td style="width: 401px;">7 empresas del sector TIC</td>
<td class="text-align-center" style="width: 151px;">2,8</td>
</tr><tr><td style="width: 401px;">6 empresas del sector Industria</td>
<td class="text-align-center" style="width: 151px;">17,6</td>
</tr><tr><td style="width: 401px;">2 empresas del sector Energía y Medio Ambiente</td>
<td class="text-align-center" style="width: 151px;">0,7</td>
</tr><tr><td style="width: 401px;">1 empresa de Otros sectores</td>
<td class="text-align-center" style="width: 151px;">0,5</td>
</tr><tr><td class="text-align-right" style="width: 401px;"><strong>Total</strong></td>
<td class="text-align-center" style="width: 151px;"><strong>38,5</strong></td>
</tr></tbody></table><p> </p>
<p>La distribución regional de las empresas en las que se ha aprobado la coinversión es la siguiente:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Comunidad Autónoma</th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de empresas</th>
</tr></thead><tbody><tr><td style="width: 401px;">Andalucía</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">Cataluña</td>
<td class="text-align-center" style="width: 151px;">8</td>
</tr><tr><td style="width: 401px;">Comunidad Valenciana</td>
<td class="text-align-center" style="width: 151px;">3</td>
</tr><tr><td style="width: 401px;">Madrid, Comunidad de</td>
<td class="text-align-center" style="width: 151px;">10</td>
</tr><tr><td style="width: 401px;">Región de Murcia</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">País Vasco</td>
<td class="text-align-center" style="width: 151px;">3</td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Con respecto a la fase de desarrollo o madurez de las empresas en las que se ha aprobado la coinversión, se clasifican en:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Madurez empresa</th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de empresas</th>
</tr></thead><tbody><tr><td style="width: 401px;">Semilla</td>
<td class="text-align-center" style="width: 151px;">8</td>
</tr><tr><td style="width: 401px;">Arranque</td>
<td class="text-align-center" style="width: 151px;">2</td>
</tr><tr><td style="width: 401px;">Otras fases iniciales</td>
<td class="text-align-center" style="width: 151px;">15</td>
</tr><tr><td style="width: 401px;">Later stage venture</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Estas coinversiones se realizarán acompañando a 19 inversores que han sido previamente homologados por Innvierte y que aportarán 45,8 millones de euros.</p>
<p class="text-align-justify">Además de aprobar la coinversión en 26 empresas, en el Consejo de junio se aprobaron dos coinversiones estratégicas (de las cuales una es empresa nueva en Innvierte) con un compromiso de 12,5 millones de euros, lo que supone un compromiso global de 51 millones de euros en inversión directa en empresas.</p>
<p class="text-align-justify">En estos Consejos, se ha aprobado también la homologación de 9 nuevos inversores privados profesionales, por lo que la cifra total de inversores homologados por Innvierte hasta la fecha asciende a 169. De éstos, 122 inversores son activos presentando solicitudes de coinversión a Innvierte.</p>
<h4> </h4>
<h4><strong>Innvierte</strong></h4>
<p class="text-align-justify">Innvierte es una iniciativa cuyo objetivo es promover la innovación empresarial mediante el apoyo a la inversión de capital riesgo en empresas de base tecnológica o innovadoras. Este programa se instrumenta a través de la sociedad de inversión colectiva de tipo cerrado Innvierte Economía Sostenible SICC S.M.E., S.A., auto gestionada y sometida a la supervisión de la Comisión Nacional del Mercado de Valores y de la que el CDTI Innovación, la agencia de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades, es accionista único.</p>
<p class="text-align-justify">Hasta la fecha, el CDTI Innovación, por medio de Innvierte, ha comprometido 1.795 M€ en 42 vehículos de inversión que han invertido en más de 271 empresas, y a través de su línea de coinversión ha comprometido directamente un importe de 522 M€ en 160 empresas.</p>
<p class="text-align-justify">Innvierte se enmarca dentro de la Estrategia Española de Ciencia, Tecnología e Innovación 2021-2027, aprobada por Acuerdo del Consejo de Ministros, en septiembre de 2020. Esta Estrategia contiene los objetivos, las reformas y las medidas que deben adoptarse en todo el ámbito de la I+D+i con el fin de impulsar su crecimiento e impacto, y es uno de los pilares sobre los que se asienta el diseño de la política del Gobierno en I+D+i para los próximos años.</p>
<p> </p>
<h4 class="text-align-justify"><strong>CDTI Innovación</strong></h4>
<p class="text-align-justify">El CDTI Innovación es la entidad pública de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades que promueve la innovación y el desarrollo tecnológico de las empresas españolas, canalizando las solicitudes de financiación y apoyo a los proyectos de I+D+I de entidades españolas en los ámbitos estatal e internacional. Contribuimos a la mejora del nivel tecnológico de las empresas españolas e impulsamos y, con una red internacional con cobertura de 51 países, acompañamos la participación española en programas internacionales de cooperación tecnológica y la transferencia internacional de su tecnología empresarial. El CDTI también apoya la creación y consolidación de empresas de base tecnológica en España.</p>
<h4 class="text-align-justify"><br /><strong>Más información:</strong></h4>
<p class="text-align-justify">Oficina de Prensa<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />
91-581.55.00</p>
<p class="text-align-justify">En Internet<br />
Sitio web: <a href="https://www.cdti.es/noticias/www.cdti.es" previewlistener="true" tabindex="-1">www.cdti.es</a><br />
En LinkedIn: <a href="https://www.linkedin.com/company/29815" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.linkedin.com/company/29815</a><br />
En X: <a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://twitter.com/CDTI_innovacion</a><br />
En YouTube: <a href="https://www.youtube.com/user/CDTIoficial" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.youtube.com/user/CDTIoficial</a></p>
<p class="text-align-justify">Este contenido es copyright © 2024 CDTI,EPE. Está permitida la utilización y reproducción citando la fuente y la identidad digital de CDTI (<a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">@CDTI_innovacion</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 03 Dec 2024 10:48:44 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22050 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con GCP, en TEBRIO, empresa biotecnológica del sector de la proteína de insectos</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-gcp-en-tebrio-empresa-biotecnologica-del-sector-de</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>CDTI Innovation invests, together with GPC, in TEBRIO, a biotechnology company in the insect protein sector. </h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 10/29/2024 - 10:46</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-10-29T12:00:00Z" class="datetime">29 October 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>CDTI Innovation invests, together with GPC, in TEBRIO, a biotechnology company in the insect protein sector. </h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">El CDTI Innovación, a través de su programa Innvierte, conjuntamente con GPC, ha alcanzado un acuerdo con los socios de TEBRIO, para realizar una nueva aportación de capital en la compañía</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-10/tebrio-coinversion_oct24.jpg" width="1024" height="512" alt="coinversión TEBRIO" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">La ronda, de un total de 30 M€, incluye venture debt y private equity. Participan, además de <a href="http://www.cdti.es/programa-innvierte" rel="noopener" target="_blank">Innvierte</a>, GPC, Banco de Santander y Sodical Instituto Financiero de Castilla y León. </p>
<p class="text-align-justify">La compañía biotecnológica, líder de la producción industrial del Tenebrio molitor en el mundo, destinará la inversión a acelerar la construcción de su nueva planta, que responderá a los altos volúmenes de fabricación comprometidos con sus clientes. </p>
<p class="text-align-justify"> </p>
<p class="text-align-justify"><img alt="Planta TEBRIO" data-entity-type="file" data-entity-uuid="425b9779-027e-41ec-816c-735f5313db9b" src="http://www.cdti.es/sites/default/files/inline-images/tebrio.jpg" width="1440" height="1080" loading="lazy" /></p>
<p class="text-align-justify"> </p>
<p class="text-align-justify"><a href="http://www.tebrio.com/" rel="noopener" target="_blank">Tebrio</a>, ubicada en Salamanca, espera multiplicar por 3 su plantilla en los próximos 2 años, cuando finalice la construcción de un complejo que ocupará un total de 90.000 metros cuadrados y le permitirá producir más de 100.000 toneladas al año de productos, respondiendo, de este modo, a los elevados volúmenes de demanda de producción y comercialización que tiene ya comprometidos con sus actuales clientes.</p>
<p class="text-align-justify">“Esta nueva ronda de inversión en nuestra compañía supone la validación de un modelo industrial basado en una tecnología propia. Un modelo que nos permite producir a precios competitivos en los mercados en los que opera, siendo así la plataforma para expandir nuestras operaciones a diferentes mercados geográficos”, subraya Adriana Casillas, CEO y cofundadora de Tebrio, compañía que por otra parte mantiene en su accionariado a Caixa Capital Risc.</p>
<p class="text-align-justify">“Desde CDTI, a través de Innvierte, llevamos como accionistas de la compañía desde 2020. Nuestra participación en la ronda actual responde a la capacidad que la compañía y sus fundadores han mostrado para posicionarse en un ámbito que consideramos estratégico con una aproximación disruptiva en tecnología e innovadora. Queremos ayudarles a ser un actor clave en un sector que consideramos estratégico a nivel país”, indica Andrés Ubierna Gorricho, Jefe del Departamento de Capitalización y Transferencia de Tecnología del Centro para el Desarrollo Tecnológico y la Innovación.</p>
<p class="text-align-justify">Jesús García, CEO de GPC, apunta que “tras 30 años de experiencia en la industria agroalimentaria, y tras valorar distintas inversiones en el sector de los insectos, nos decantamos por Tebrio debido a la calidad de sus productos, junto con una interesante rentabilidad financiera. Todo ello ligado a las elevadas garantías de seguridad biológica que ofrece el insecto Tenebrio molitor, lo que garantiza nuestra inversión. Nos enorgullece trabajar con socios que comparten nuestros valores y que están comprometidos con el desarrollo de soluciones que beneficien a todos. Juntos, estamos sembrando las semillas de un cambio positivo, cultivando un mundo más justo y saludable para generaciones venideras”.</p>
<p class="text-align-justify">Tebrio cuenta actualmente con una planta de producción de 3.500 metros cuadrados, de la cual salen al año cientos de toneladas de proteína, grasa, biofertilizante y quitosano. Tebrio comenzó a operar en 2014 con la misión de aportar soluciones innovadoras y 100% sostenibles para la industria agroalimentaria. Sus ejes de actuación se centran en la seguridad alimentaria, la sostenibilidad y el modelo de economía circular.</p>
<p class="text-align-justify"> </p>
<h4 class="text-align-justify"><strong>GPC</strong></h4>
<p class="text-align-justify">GPC es una Family Office con sede en Madrid, si bien sus oficinas operativas se encuentran en Salamanca. Dado el carácter profesional de sus integrantes, GPC tiene entre sus principales proyectos las inversiones estratégicas en Start ups y sociedades relacionadas con el ámbito agroalimentario, en el mundo Pharma así como en el ámbito de las energías renovables, sin menoscabo de cualquier otro proyecto empresarial y con un enfoque claro en la sostenibilidad y el impacto social.</p>
<p class="text-align-justify"> </p>
<h4><strong>CDTI Innovación</strong></h4>
<p class="text-align-justify">El CDTI Innovación es la entidad pública de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades que promueve la innovación y el desarrollo tecnológico de las empresas españolas, canalizando las solicitudes de financiación y apoyo a los proyectos de I+D+I de entidades españolas en los ámbitos estatal e internacional. Contribuimos a la mejora del nivel tecnológico de las empresas españolas e impulsamos y, con una red internacional con cobertura de 51 países, acompañamos la participación española en programas internacionales de cooperación tecnológica y la transferencia internacional de su tecnología empresarial. </p>
<p class="text-align-justify">Adicionalmente, a través de la iniciativa Innvierte Economía Sostenible, apoya y facilita la capitalización de empresas tecnológicas. Desde 2012 y hasta la fecha, el CDTI Innovación, por medio de Innvierte, ha comprometido 1.376 M€ en 37 vehículos de inversión que han invertido en más de 275 empresas, y a través de su línea de coinversión ha comprometido directamente un importe de más de 493 M€ en al menos 152 empresas.</p>
<p class="text-align-justify"> </p>
<h4><strong>Más información:</strong></h4>
<p>Oficina de Prensa<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />
91-581.55.00</p>
<p>En Internet<br />
Sitio web: <a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br />
En Linkedin: <a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https://www.linkedin.com/company/29815</a><br />
En X: <a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https://twitter.com/CDTI_innovacion</a><br />
En Youtube: <a href="https://www.youtube.com/user/CDTIoficial">https://www.youtube.com/user/CDTIoficial</a></p>
<p>Este contenido es copyright © 2024 CDTI,EPE. Está permitida la utilización y reproducción citando la fuente y la identidad digital de CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI_innovacion</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Mon, 28 Oct 2024 16:03:44 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">21865 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con INVEREADY FIRST CAPITAL III PARALLEL, F.C.R. e INVEREADY FIRST CAPITAL III S.C.R.E., S.A., en UNION AVATARS, empresa que desarrolla una plataforma de creación de avatares</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-inveready-first-capital-iii-parallel-fcr-e-inveready</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>CDTI Innovation invests, together with INVEREADY FIRST CAPITAL III PARALLEL, F.C.R. and INVEREADY FIRST CAPITAL III S.C.R.E., S.A., in UNION AVATARS, a company developing an avatar creation platform.</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Fri, 10/18/2024 - 14:09</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-10-18T12:00:00Z" class="datetime">18 October 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>CDTI Innovation invests, together with INVEREADY FIRST CAPITAL III PARALLEL, F.C.R. and INVEREADY FIRST CAPITAL III S.C.R.E., S.A., in UNION AVATARS, a company developing an avatar creation platform.</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte INVEREADY FIRST CAPITAL III PARALLEL, F.C.R. e INVEREADY FIRST CAPITAL III S.C.R.E., S.A., has reached an agreement with Union Avatars (Linking Realities, S.L.), to invest in the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-10/union_avatars_coinversion_cdti_oct_2024.jpg" width="960" height="480" alt="Coinversión UNION AVATARS" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify"><a href="https://unionavatars.com" rel="noopener" target="_blank">Union Avatars</a>has developed a platform to create avatars to their customers can offer a representation of its users, whether in video games, social networks, virtual reality worlds gamificación or blur the lines between the virtual world and reality, through the use of technology on the 3D virtual worlds and help shape the future of virtual identity.</p>
<p class="text-align-justify"><img alt="avatars" data-entity-type="file" data-entity-uuid="cdf423b3-0b03-4c5a-99dc-5e1ca2b50760" src="http://www.cdti.es/sites/default/files/inline-images/group_avatars_logo.jpg" width="1920" height="1080" loading="lazy" /></p>
<h4 class="text-align-justify"> </h4>
<h4 class="text-align-justify"><strong>INVEREADY</strong></h4>
<p class="text-align-justify"><a href="https://inveready.com/" rel="noopener" target="_blank">Inveready</a>it is an asset manager in spain that, through its various investment strategies (Venture Capital, Venture Debt, Private Equity, Public Equity, etc.), is able to provide financing solutions to businesses throughout their life cycle.<br />
</p>
<h4><strong>CDTI Innovation</strong></h4>
<p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p>
<p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. Since 2012 and to date, the CDTI Innovation, through Innvierte, committed 1,376 M €in 37 investment vehicles that have invested in more than 275 companies, and through its joint investment line directly committed an amount of more than 493 M €in at least 152 companies.</p>
<p> </p>
<h4><strong>More information:</strong></h4>
<p>Office of the press<br /><br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br /><br />
91-581.55.00</p>
<p>On The Internet<br /><br />
Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br /><br />
In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br /><br />
X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br /><br />
On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p>
<p>This content is copyright © 2024 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 18 Oct 2024 11:48:54 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">21827 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con ELEWIT, S.A. y EIT InnoEnergy, en ZELEROS GLOBAL, S.L., compañía que desarrolla tecnologías hyperloop y ofrece soluciones de electrificación y automatización en el ámbito de la movilidad</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-elewit-sa-y-eit-innoenergy-en-zeleros-global-sl</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with ELEWIT, S.A. and EIT InnoEnergy, GLOBAL ZELEROS, S.L., company that develops hyperloop technologies and offers solutions of electrification and automation in the area of mobility</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Thu, 10/10/2024 - 08:12</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-10-07T12:00:00Z" class="datetime">07 October 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with ELEWIT, S.A. and EIT InnoEnergy, GLOBAL ZELEROS, S.L., company that develops hyperloop technologies and offers solutions of electrification and automation in the area of mobility</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte ELEWIT, S.A. and EIT InnoEnergy, has reached an agreement with GLOBAL ZELEROS, S.L., to enter the capital of the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-10/zeleros-coinversinon_oct24.jpg" width="1024" height="512" alt="Coinversión ZELEROS" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">Pioneers in the transition towards a more intelligent mobility and fair,<a href="http://www.zeleros.com/" rel="noopener" target="_blank">Zeleros</a>is presented as a partner of electrification, automation and hyperloop development, offering customized products and services and brand España.</p>
<p class="text-align-justify">Founded in 2016, the company is a pioneer in the development of technologies hyperloop, ground transportation faster. After reaching a crucial stage of technological validation by 2023, the company expanded its commercial approach towards niche business related to allow further progress in this project. With this, use their know-how acquired in disruptive initiatives aimed at providing an Agile engineering complex projects of electrification and automation, and with a strong focus on efficiency.</p>
<p class="text-align-justify">In parallel, Zeleros remains active in the development of hyperloop and participating in the european industrial partnership Hyperloop Development Program, as well as in projects such as Rail Joint Undertaking (the association of european railway innovation).</p>
<p class="text-align-justify">Thus, Zeleros is committed to sustainability and is aware that the conventional transport is responsible for approximately 25 per cent of greenhouse gases released into the atmosphere, accelerating global warming. Therefore, the company works to offer the possibility of electrification and reduce direct emissions from transport, providing a sustainable and efficient mobility for society.</p>
<p class="text-align-justify"><img alt="Siste" data-entity-type="file" data-entity-uuid="94343506-7283-4621-91aa-0852d67adaca" src="http://www.cdti.es/sites/default/files/inline-images/zeleros-2_0.jpg" width="935" height="526" loading="lazy" /></p>
<p class="text-align-justify">Sistema hyperloop of Zeleros</p>
<p class="text-align-justify"> </p>
<p class="text-align-justify"><img alt="" data-entity-type="file" data-entity-uuid="ce83cb76-d18a-4d96-b879-45a108d987db" src="http://www.cdti.es/sites/default/files/inline-images/zeleros-3_0.jpg" width="949" height="534" loading="lazy" /></p>
<p class="text-align-justify">Batería Latitude de Zeleros</p>
<p class="text-align-justify"> </p>
<h4 class="text-align-justify"><strong>ELEWIT, S.A.</strong></h4>
<p class="text-align-justify"><a href="https://www.elewit.ventures/es" rel="noopener" target="_blank">Elewit</a>it is the technology platform manager Redeia, global energy vital infrastructure and connectivity. Born in 2019 to address the challenges of transition and the universal connectivity in electricity and telecommunications, respectively. Its mission includes the momentum of energy transition and the digital and contribute to building a more sustainable future.</p>
<p class="text-align-justify">Through its Corporate Venture Capital invested directly in eight startups. Moreover, it is part of two specialized funds in Deep tech (Adara and Cardumen Capital) and, recently, has invested in Adara Ventures Energy I, a fund to advance the progress of energy transition, together with Adara Ventures and Group Dunes, peruvian subsidiary Group Energy Bogotá.</p>
<p class="text-align-justify"> </p>
<h4 class="text-align-justify"><strong>EIT InnoEnergy</strong></h4>
<p class="text-align-justify"><a href="http://www.innoenergy.com/" rel="noopener" target="_blank">EIT InnoEnergy</a>operates in the centre of energy transition and is the main engine of innovation in sustainable energy, providing the technology and skills necessary to accelerate the european Green, move towards the goal of decarbonisation of europe and enhance energy security.</p>
<p class="text-align-justify">EIT InnoEnergy es la impulsora de tres iniciativas europeas estratégicas que incluyen la<a href="https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.eba250.com%2F&data=04%7C01%7Crenata.hofmeister%40innoenergy.com%7Cb3aad4b4d6a545365a1e08d90a502437%7C435e0b8676ae4629aa04b81daf18c473%7C0%7C0%7C637552161582076115%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=7vmEYA%2FqZ4rPnQWTBVdVOIxScEGKHOS8iVv029y97q0%3D&reserved=0" rel="noopener" target="_blank">European Alliance of Batteries</a>(EBA in its initials in english),<a href="https://eghac.com/" rel="noopener" target="_blank">European centre for hydrogen Acceleration Green</a>(EGHAC in its initials in english) and<a href="https://solaralliance.eu/" rel="noopener" target="_blank">European Alliance of Photovoltaic Solar industry</a>(ESIA in its initials in english).</p>
<p class="text-align-justify">EIT InnoEnergy was founded in 2010 and has the support of the european institute of innovation and technology (EIT), an independent body of the eu created in 2008 to drive innovation and entrepreneurship throughout Europe.</p>
<p class="text-align-justify"> </p>
<h4><strong>CDTI Innovation</strong></h4>
<p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p>
<p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. Since 2012 and to date, the CDTI Innovation, through Innvierte, committed 965 M €in 32 investment vehicles that have invested in more than 270 companies, and through its joint investment line directly committed an amount of more than 485 M €in at least 152 companies.</p>
<p class="text-align-justify"> </p>
<h4><strong>More information:</strong></h4>
<p>Office of the press<br /><br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br /><br />
91-581.55.00</p>
<p>On The Internet<br /><br />
Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br /><br />
In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br /><br />
X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br /><br />
On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p>
<p>This content is copyright © 2024 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Mon, 07 Oct 2024 08:24:22 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">21736 at http://www.cdti.es</guid>
</item>
</channel>
</rss>